NCT06084533Enrolling by invitation
CS1P1 PET Studies of Neuroinflammation in Parkinson Disease
Source: ClinicalTrials.gov · Last updated 2 Apr 2026
Brief summary (registry, in English)
Parkinson disease (PD) is a progressive neurological disorder strongly linked to advancing age that results in decline in mobility and thinking. Based on prior research, the investigators think that small amounts of inflammation in the brain may contribute to the mobility and thinking problems in people with PD. They are trying to measure inflammation in the brain in order to understand how this inflammation could be contributing to the symptoms of PD. This study involves a brain positron emission tomography (PET) scan with a new, investigational radioactive tracer called \[11C\]-CS1P1 to identify inflammation in the brain.The goal of this project is to quantify neuroinflammation with \[11C\]-CS1P1 PET and compare to motor and cognitive function in participants with various stages of severity of PD compared to controls.
- Status (registry)
- Enrolling by invitation
- Study type
- Observational
- Enrollment
- 80 (estimated)
- First submitted
- 10 Oct 2023
- Start date
- 10 Jan 2024
- Primary completion date
- 1 Feb 2029
- Lead sponsor
- Washington University School of Medicine
- Diseases
- Parkinson disease
- NCT number
- NCT06084533
What you commit to
- Study type: Observational
- Planned participants: 80
- From 10 Jan 2024 to the primary completion date, 1 Feb 2029
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- major drug abuse
- chronic treatment with immunomodulatory or anti-inflammatory medications
Other illness
- any history of other neurologic illness (e.g. stroke, seizure, multiple sclerosis)
- history of brain surgery or major head trauma
- major medical/systemic illness
- severe psychiatric illness (e.g. bipolar disorder, schizophrenia)
- history of long term use of anti-dopaminergic medication
Other
- weight over 300 lbs
- contraindication to or inability to tolerate MRI
Who the study is looking for
- Parkinson Disease (PD) participants must be at least 50 years old and meet clinical diagnostic criteria of idiopathic PD.
- Control participants must be at least 50 years old and not have PD, no first-degree family member with PD, and no evidence of PD or dementia on examination.
Age in the registry: 50 years to - · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Washington University School of Medicine Coordinator of this site? Confirm its status | St Louis | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.